All of the presentations made during Science Day will be considered off-the-record, and are not to be used for any other purpose in the litigation other than the Court’s benefit.
New York, New York (PRWEB) May 26, 2015
The federal court overseeing more than 400 Xarelto lawsuits (http://www.xareltolawsuit2015.com/) filed on behalf of individuals who were allegedly injured by the medication has established procedures for the litigation’s June 11th Science Day. According to an Order issued in the U.S. District Court, Eastern District of Louisiana, on May 21st, topics to be addressed include Xarelto adverse events, clinical trials pertaining to the drug, the use of blood test based testing with Xarelto, and Xarelto pharmacology. All presentations will be made by scientists and physicians, and the Court will have the opportunity to question these experts as it deems appropriate. The Order stipulates that the parties must provide the Court with copies of their presentations on or before June 5, 2015. (In Re: Xarelto Products Liability Litigation, No. 2592)
“All of the presentations made during Science Day will be considered off-the-record, and are not to be used for any other purpose in the litigation other than the Court’s benefit. Our Firm is representing clients in federal Xarelto lawsuits, and this proceeding will serve to apprise the Court of scientific and medical issues that may prove relevant to our clients’ claims,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered a life-threatening internal bleeding and other dangerous complications related to its use.
According to court documents, Xarelto was initially approved by the U.S. Food & Drug Administration in 2011, and is now indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. The Xarelto label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
According to court documents, all of the Xarelto lawsuits pending in the Eastern District of Louisiana involve similar allegations regarding the medication’s potential to cause uncontrollable internal bleeding and other serious side effects, including strokes, deep vein thrombosis and pulmonary embolism. Plaintiffs further allege that the manufacturers of Xarelto were wrong to market the blood thinner as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, they point out that bleeding associated with warfarin can be stopped via the administration of vitamin K, while there is currently no approved antidote to stop Xarelto bleeding.
In addition to the Xarelto lawsuits pending in the federal multidistrict litigation, at least 243 similar claims have been filed in a Pennsylvania mass tort litigation now underway in the Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)
Xarelto patients may be entitled to compensation if they experienced dangerous episodes of internal bleeding or other complications allegedly related to its use. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP